Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...

Nifty Pharma dropped 0.66% at intraday as it underperformed benchmark Nifty 50 which dropped 0.46% at intraday.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter ...

Aurobindo Pharma Limited announced mixed performance during the quarter ended June 2025. The business reported a consolidated ...

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT, citing API sales and US market revenue decline. The company's ...

Indian drugmakers are responding with geographic diversification, supply-chain resilience and acquisition of US assets to ...

Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.

Mumbai: Aurobindo Pharma Limited on Monday reported a 10.2 per cent year-on-year (YoY) drop in consolidated net profit to Rs ...